Humacyte raises $20 million in registered direct offering

Humacyte Inc. (NASDAQ: HUMA) announced it has entered into a securities purchase agreement with institutional investors for a registered direct offering of 25 million shares of common stock, according to a company statement.

The biotechnology company expects to receive gross proceeds of $20 million from the offering before deducting expenses. The transaction is expected to close on or about March 20, 2026, subject to customary closing conditions.

The offering was led by a life science dedicated investor and a long-only mutual fund, both described as new institutional investors. Titan Partners, a division of American Capital Partners, is serving as sole placement agent.

Humacyte plans to use the net proceeds to fund commercialization of its Symvess product in the vascular trauma indication and to support a planned Biologics License Application supplement filing in a hemodialysis indication. The funds will also support the upcoming Phase 3 results readout, pipeline development activities, and general corporate purposes.

The Durham, North Carolina-based company develops bioengineered human tissues and commenced the U.S. commercial launch of Symvess, its first FDA-approved product, in the first quarter of 2025.

The securities are being offered through a prospectus supplement and accompanying prospectus under a shelf registration statement that was filed with the Securities and Exchange Commission on September 12, 2025, and declared effective on September 22, 2025.

You May Also Be Interested In

• Autonomix Medical raises $2.6M via warrant inducement agreement
• Research Alliance Corporation IV prices $75M IPO on Nasdaq
• GH Power to go public via merger with Matinas BioPharma